Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,558,331
  • Shares Outstanding, K 52,503
  • Annual Sales, $ 270,250 K
  • Annual Income, $ 21,410 K
  • 60-Month Beta 1.12
  • Price/Sales 27.56
  • Price/Cash Flow 100.62
  • Price/Book 6.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.28
  • Number of Estimates 5
  • High Estimate 0.31
  • Low Estimate 0.26
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
138.40 +2.88%
on 09/21/20
157.46 -9.57%
on 09/01/20
-9.26 (-6.11%)
since 08/21/20
3-Month
109.38 +30.17%
on 06/25/20
159.97 -11.00%
on 08/03/20
+22.84 (+19.11%)
since 06/23/20
52-Week
72.32 +96.88%
on 10/02/19
159.97 -11.00%
on 08/03/20
+61.29 (+75.58%)
since 09/23/19

Most Recent Stories

More News
Genocea to Initiate a Phase I/II Oncology Study on GEN-011

Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.

EBS : 102.23 (+1.47%)
HZNP : 79.78 (+2.07%)
RGEN : 142.38 (-1.10%)
GNCA : 2.14 (-12.65%)
Why Repligen Corporation (RGEN) Could Be an Impressive Growth Stock

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen Corporation (RGEN).

RGEN : 142.38 (-1.10%)
Why Is Repligen (RGEN) Down 0.7% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RGEN : 142.38 (-1.10%)
Insights on the Prepacked Chromatography Columns Global Market to 2025 - Featuring Repligen, Shimadzu & Tosoh Among Others

, /PRNewswire/ -- The report has been added to offering.

RGEN : 142.38 (-1.10%)
Axsome's NDA Filing for Migraine Candidate in Q4 on Track

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.

EBS : 102.23 (+1.47%)
HZNP : 79.78 (+2.07%)
RGEN : 142.38 (-1.10%)
AXSM : 77.59 (-4.53%)
Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline

Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.

EBS : 102.23 (+1.47%)
HZNP : 79.78 (+2.07%)
RGEN : 142.38 (-1.10%)
SRNE : 9.60 (-10.95%)
Looking for Earnings Beat? Buy These 5 Stocks With Potential

These top-ranked stocks are likely to beat on their bottom line in the next releases.

NBL : 8.50 (-4.82%)
EAT : 43.65 (-2.26%)
BJ : 41.40 (+0.63%)
RGEN : 142.38 (-1.10%)
W : 286.72 (-5.74%)
Repligen Corp Set to Possibly Pullback After Yesterday's Rally of 1.20%

Repligen Corp (NASDAQ:RGEN) traded in a range yesterday that spanned from a low of $147.31 to a high of $149.73. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

RGEN : 142.38 (-1.10%)
Albireo Down on Unimpressive Data From Mid-Stage NASH Study

Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.

EBS : 102.23 (+1.47%)
HZNP : 79.78 (+2.07%)
RGEN : 142.38 (-1.10%)
ALBO : 35.16 (-2.36%)
Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%

Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

RGEN : 142.38 (-1.10%)
EIGR : 9.32 (-3.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RGEN with:

Business Summary

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide....

See More

Key Turning Points

2nd Resistance Point 147.44
1st Resistance Point 144.91
Last Price 142.38
1st Support Level 140.94
2nd Support Level 139.51

See More

52-Week High 159.97
Last Price 142.38
Fibonacci 61.8% 126.49
Fibonacci 50% 116.15
Fibonacci 38.2% 105.80
52-Week Low 72.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar